Skip to main content
Opthea Ltd logo

Opthea Ltd — Investor Relations & Filings

Ticker · OPT ISIN · US68386J2087 LEI · 549300Q5FMFDLP46SF83 ASX Manufacturing
Open in API
Filings indexed 1,390 across all filing types
Latest filing 2020-10-15 Regulatory Filings
Country AU Australia
Listing ASX OPT

About Opthea Ltd

https://opthea.com/

Opthea is a clinical-stage biopharmaceutical company focused on developing novel therapies for vision-threatening retinal diseases, particularly wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The company's lead product candidate, sozinibercept, is a first-in-class biologic 'trap' inhibitor targeting Vascular Endothelial Growth Factors C and D (VEGF-C and VEGF-D). Sozinibercept is being developed for administration in combination with standard-of-care anti-VEGF-A therapies. This dual-pathway inhibition aims to deliver superior visual outcomes by more comprehensively blocking the mechanisms that contribute to disease progression, addressing the limitations of current treatments that only target VEGF-A. The therapy is being evaluated in late-stage pivotal clinical trials for wet AMD.

Recent filings

Filing Released Lang Actions
Trading Halt 2 pages 247.4KB
Regulatory Filings Classification · 95% confidence The document is a market announcement dated 16 October 2020 regarding a trading halt requested by Opthea Limited. It references a pending announcement about the outcome of a US initial public offering (IPO) of American Depositary Shares and concurrent Nasdaq listing. The document is short (2233 characters) and does not contain financial data or detailed report content. It is an announcement about a trading halt pending a future announcement, not a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-10-15 English
8-A12B
Regulatory Filings
2020-10-14 English
Becoming a substantial holder 61 pages 306.8KB
Major Shareholding Notification Classification · 100% confidence The document is titled 'Form 603' and references the Corporations Act Section 671B, which pertains to notices of substantial shareholdings. It details the initial substantial holder's name, voting power, relevant interests, registered holders, consideration paid, and associates. The content is focused on reporting changes in significant share ownership levels, including detailed tables of securities held and transactions. There is no financial performance data, management discussion, or audit information. The document is a regulatory filing specifically notifying a substantial shareholding event, which aligns with the category 'Major Shareholding Notification' (MRQ). The document length is substantial and contains detailed data, confirming it is the report itself, not just an announcement.
2020-10-14 English
Initial Director's Interest Notice - JL 2 pages 134.2KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities and contracts, specifically noting nil holdings and contracts. This type of document is a report of personal share transactions or interests by company directors. It is not a full financial report, announcement of voting results, or other corporate filings. The document length is short and focused solely on director's dealings. Therefore, it fits the category of Director's Dealing (DIRS).
2020-10-14 English
Opthea Chairman Address to the 2020 Annual General Meeting 3 pages 177.9KB
AGM Information Classification · 95% confidence The document is titled 'Opthea Chairman’s Address to the 2020 Annual General Meeting' and contains speeches from the Chairman, incoming Chairman, and CEO at the AGM. It discusses company achievements, strategic goals, leadership changes, and future outlook. There are no financial statements or detailed financial data presented. The content is typical of presentations and materials shared during an Annual General Meeting. The document length is about 10,380 characters, which is consistent with a detailed AGM address rather than a brief announcement or a full annual report. Therefore, the document fits the category of AGM Information (AGM-R).
2020-10-11 English
Trading Halt 2 pages 246.8KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Opthea Limited dated 12 October 2020, requesting a trading halt pending the release of an announcement related to a proposed US initial public offering and Nasdaq listing. The text is short (2296 characters) and primarily concerns the request for a trading halt, not the actual announcement or report of the IPO or listing. There is no financial data, report content, or detailed presentation included. This fits the category of a Regulatory Filing (RNS) as it is a compliance-related announcement that does not fit into other specific categories like Capital/Financing Update or IPO filings. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-10-11 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.